Theseus Pharmaceuticals, Inc.
NASDAQ: THRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Iain D. Dukes DPHIL,
- Employees
- 38
- Headquarters
- Cambridge, United States
- IPO year
- 2021
- Market cap
- $181.5M
- Website
- https://theseusrx.com
Loading THRX…
Loading profile data…Frequently asked questions about THRX
What does Theseus Pharmaceuticals, Inc. (THRX) do?
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a f...
Where does THRX trade?
Theseus Pharmaceuticals, Inc. (THRX) trades on the NASDAQ Global Select.
What sector is THRX in?
Theseus Pharmaceuticals, Inc. (THRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Theseus Pharmaceuticals, Inc.?
Iain D. Dukes DPHIL, is the chief executive officer of Theseus Pharmaceuticals, Inc. (THRX).
Where is Theseus Pharmaceuticals, Inc. headquartered?
Theseus Pharmaceuticals, Inc. is headquartered in United States.
Does THRX pay a dividend?
Theseus Pharmaceuticals, Inc. (THRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did THRX go public?
Theseus Pharmaceuticals, Inc. (THRX) completed its initial public offering in 2021.